Effect of spironolactone on ischemia reperfusion injury in renal transplant recipients

Effect of mineralocorticoid receptor blockade on ischemia / reperfusion injury in renal transplant recipients: A pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN01577227

Enrollment

Registered

2013-01-23

Start date

2013-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia reperfusion injury Circulatory System

Interventions

The patients will be randomized to receive 50 or 100 mg of spironolactone (Sp) or placebo orally twice daily (BID), 3 days prior to transplant surgery and 50 or 100 mg of Sp or placebo orally BID du

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age of 18 years or older, male and female 2. Receipt of a live-donor kidney

Exclusion criteria

Exclusion criteria: 1. Multi-organ transplant 2. Deceased-donor kidney 3. Induction with thymoglobuline

Design outcomes

Primary

Measure	Time frame
Reduction of urinary biomarkers of kidney injury [ Heat shock protein 72 (HsP72), Interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1)] at baseline, day 1, and 5 post transplantation.	—

Secondary

Measure	Time frame
1. Reduction of oxidative stress 2. Change in urinary hydrogen peroxide excretion 3. Change in urinary nitrates excretion All measures at baseline, day 1, and 5 post transplantation	—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026